Glucocorticoid receptors in human sensory neurons co-localize extensively with the pain peptide CGRP, and their activation reduces pain while mineralocorticoid receptors promote it — revealing a new mechanism for optimizing steroid-based pain therapy.
GR + CGRP colocalizationFor the first time in human tissue, glucocorticoid receptors were shown to be concentrated on the same pain-sensing neurons that produce CGRP — directly linking steroid therapy to neuropeptide pain signaling.
What the researchers found
Glucocorticoid receptors (GR) are abundantly expressed in human dorsal root ganglion (DRG) sensory neurons — the same neurons that produce CGRP, the key pain-signaling neuropeptide. Specifically, GR was found to co-localize extensively with CGRP in pain-sensing C-fibers and Aδ-fibers, and was concentrated in medium-diameter neurons (40-65 μm). In animal models, GR activation reduced inflammatory pain through rapid non-genomic mechanisms, while mineralocorticoid receptors (MR) had the opposite effect — promoting pain. Clinically, epidural steroid injections provided at least 3 months of pain relief in patients with chronic radicular pain. Together, the findings suggest that steroids relieve pain partly by acting on GR in CGRP-producing pain neurons, and that MR blockade could enhance this effect.
Why it matters
Epidural steroid injections are among the most common procedures for chronic back and nerve pain, yet the molecular basis for how steroids relieve pain at the spinal level has been poorly understood. This study provides the first comprehensive human tissue evidence that steroid receptors are concentrated specifically on CGRP-producing pain neurons — revealing a direct link between steroid therapy and the peptide signaling system that drives pain. The discovery that MR has an opposing, pain-promoting effect opens a new therapeutic angle: combining GR activation with MR blockade could improve steroid-based pain treatments.
The numbers in context
GR colocalized with CGRP in C-fibers and Aδ-fibers · Medium-diameter neurons (40-65 μm) · ≥3 months clinical analgesia · GR = pain-reducing · MR = pain-promoting
How the study worked
Multi-approach translational study: (1) mRNA profiling and immunofluorescence confocal microscopy of human and rat DRG tissue to map GR and MR expression relative to pain markers including CGRP; (2) preclinical experiments in rat pain models testing GR activation and MR blockade on inflammatory pain via rapid non-genomic mechanisms; (3) clinical evaluation of transforaminal plus caudal epidural steroid injection in patients with chronic radicular pain, assessing analgesia duration.
Who was studied
Human and rat DRG tissue analyses, plus clinical evaluation of patients with chronic radicular pain receiving epidural steroid injections
What this study cannot tell us
The human tissue component is descriptive (expression mapping) rather than functional. The clinical component appears observational rather than a controlled trial. The study doesn't directly demonstrate that GR activation reduces CGRP release in human DRG — this link is inferred from colocalization. The 3-month clinical follow-up is relatively short for chronic pain. The number of human DRG samples analyzed and the clinical patient cohort size are not specified in the abstract.
How to read the evidence
This is a strong translational study combining human tissue analysis, animal experiments, and clinical outcomes — three complementary lines of evidence. The molecular findings in human DRG are novel and well-characterized. However, the clinical component appears observational, and direct functional evidence of GR modulating CGRP release in humans is inferred rather than demonstrated.
When this study was published
Published in 2026, this is a very recent study that provides molecular-level understanding of a clinical practice (epidural steroid injections) that has been used for decades without clear mechanistic explanation. The findings are immediately relevant to pain medicine.
The bigger picture
Epidural steroid injections are performed millions of times per year worldwide for back pain and sciatica, yet the field has debated for decades whether they work and how. This study provides a molecular explanation: steroids act directly on the neurons that produce CGRP — the same peptide targeted by the new generation of migraine drugs. This creates an unexpected bridge between chronic pain management and migraine therapeutics: both involve CGRP-producing sensory neurons, and both can be modulated by targeting receptors on those neurons. The MR finding is particularly exciting — it suggests that adding an MR blocker to steroid therapy could enhance pain relief.
Questions still open
- Would combining a glucocorticoid with a mineralocorticoid receptor blocker in epidural injections provide better or longer-lasting pain relief?
- Does GR activation directly reduce CGRP release from sensory neurons, and would this complement anti-CGRP antibody therapy for pain?
- Are there patient populations where MR expression is elevated in DRG neurons, predisposing them to chronic pain?
Common questions
How do epidural steroid injections reduce pain?
Could steroid injections for pain be improved?
Read the original research
Human DRG Glucocorticoid Receptor Profiling Reveals Targets for Regionally Delivered Steroid Analgesia.
Cells, 15(3)
Citation
Mousa, Shaaban A; Metwally, Elsayed Y; Li, Xiongjuan; Tafelski, Sascha; Retana Romero, Oscar Andrés; Piontek, Jörg; Treskatsch, Sascha; Schäfer, Michael; Shaqura, Mohammed. (2026). Human DRG Glucocorticoid Receptor Profiling Reveals Targets for Regionally Delivered Steroid Analgesia.. Cells, 15(3). https://doi.org/10.3390/cells15030223